Toronto, Ontario – The Newswire – September 15, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is thrilled to announce that it will be a sponsor for the German Society for Pediatric Cardiology and Congenital Heart Defects Echo Advanced Workshop being held on September 16th, 2023, in Bad Oeynhausen. As a sponsor, Ventripoint will have the opportunity to showcase the VMS+’s AI technology with 2D echo in a practical hands-on session led by PD Dr. Kai Thorsten Laser.

The German Society for Pediatric Cardiology and Congenital Heart Defects is a non-profit medical society that aims to promote research, diagnostics, and the prevention of congenital and acquired heart disease. The emphasis on education compliments the diagnostic capabilities of Ventripoint’s VMS+, which will be highlighted during the practical session.

The session leader, PD Dr. Laser, is the Deputy Director and Senior Physician for the Department of Pediatric Cardiology and Congenital Heart Defects of Herz-und Diabetesszentrium North Rhine-Westfalia | HDZ. Dr. Laser’s session will discuss how the VMS+ is an effective and reliable tool in the assessment of congenital heart disease. The session will have a maximum of 30 participants so that each physician can receive hands-on learning experience. The session will discuss twenty different cases and in the practical portion of the workshop will include patients to investigate.

“We are thrilled to have an opportunity for the VMS+ to be discussed by someone as knowledgeable about the product as Dr. Laser during the DGPK Echo Advanced Workshop. This workshop will provide attendees with real life examples of how the VMS+ is a powerful cardiac diagnostic tool,” stated Dr. Alvira Macanovic, President and CEO of Ventripoint Diagnostics.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Jonathan Robinson

This email address is being protected from spambots. You need JavaScript enabled to view it.

416-669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.